Rafael Holdings, Inc. (NYSE:RFL) Holds Annual Meeting of Stockholders and Elects Board of Directors

Rafael Holdings, Inc. recently held its Annual Meeting of Stockholders on January 9, 2025. At the meeting, several important matters were voted on, including the election of nominees to the Board of Directors, the ratification of the appointment of the independent registered public accounting firm, and the approval of an amendment to the company’s 2021 Equity Incentive Plan.

The Board of Directors nominees, Susan Y. Bernstein, Stephen M. Greenberg, Howard S. Jonas, Mark N. Stein, and Michael J. Weiss, were each elected for a one-year term based on the votes received. The votes for each nominee reflected a strong majority in favor of their election, with percentages ranging from 85.93% to 89.21%.

Furthermore, the appointment of CohnReznick LLP as Rafael Holdings, Inc.’s independent registered public accounting firm for the Fiscal Year ending July 31, 2025, was also ratified. The overwhelming majority of votes (99.93%) were in favor of this appointment.

Lastly, shareholders voted in connection with the approval of an amendment to the company’s 2021 Equity Incentive Plan. This amendment aimed to increase the number of shares of the company’s Class B common stock available for the grant of awards by 750,000. The votes cast showed a majority in favor of the amendment, with 85.25% in support.

The results of these voting matters reflect the confidence and support of the company’s shareholders in the decisions made at the Annual Meeting. Rafael Holdings, Inc. continues to prioritize transparency and effective governance, as evidenced by the smooth conduct of the meeting and the positive outcomes of the shareholder votes.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Rafael’s 8K filing here.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.